Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

The Treatment Journey With CAR T-Cell Therapy: Recommendations for Care Teams, Patients, and Caregivers
  • CE

Credits Available
Registered Nurses: 2.0 Nursing contact hours
Released: July 8, 2020 Expiration: July 7, 2021
Start Activity
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Celgene Corporation
person default
Caron A. Jacobson, MD
Program Director
Alix Beaupierre, BSN, RN, OCN
person default
Kathleen McDermott, RN, BSN, OCN, BMTCN

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply the latest safety and efficacy data for currently approved and emerging CAR T-cell therapy in clinical decision-making for the treatment of leukemia, lymphoma, and multiple myeloma
  • Discuss key education elements for CAR T-cell therapy including considerations for each stage of therapy and specific recommendations for care teams, patients, and caregivers
  • Based on the current best evidence, implement strategies for managing toxicities associated with CAR T-cell therapy
  • Recall ongoing clinical trials evaluating CAR T-cell therapy for the treatment of leukemia, lymphoma, and multiple myeloma to aid in the referral of appropriate patients

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Caron A. Jacobson, MD

Assistant Professor
Division of Medical Oncology
Department of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Caron A. Jacobson, MD, has disclosed that she has received consulting fees from Bristol-Myers Squibb, Celgene, Humanigen, Kite, Lonza, Nkarta, Novartis, and Precision Biosciences.

Faculty

Alix Beaupierre, BSN, RN, OCN

Transplant and Cellular Therapy Nurse Coordinator
Blood and Marrow Transplant and Cellular Immunotherapy
Moffitt Cancer Center
Tampa, Florida

Alix Beaupierre, BSN, RN, OCN, has disclosed that she has received fees for non-CME/CE services from Kite.
Kathleen McDermott, RN, BSN, OCN, BMTCN

Immune Effector Cell (IEC)  Program Nurse Navigator
Hematologic Malignancies
Dana-Farber Cancer Institute
Boston, Massachusetts

Kathleen McDermott, RN, BSN, OCN, BMTCN, has disclosed that that she has received consulting fees from Celgene and Kite/Gilead Sciences.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended for oncology nurses, nurse practitioners, and clinical nurse specialists who care for patients with leukemia, lymphoma, or multiple myeloma.

Goal

The goal of this activity is to improve the knowledge, competence, and performance of oncology nurses, nurse practitioners, and clinical nurse specialists in treating patients with leukemia, lymphoma, or multiple myeloma and key elements for education along the treatment journey with CAR T-cell therapy, including considerations for each stage of therapy and specific recommendations for care teams, patients, and caregivers.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 08, 2020, through July 07, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Integration of CAR T-Cell Therapy Into the Management of Hematologic Malignancies (37 mins)
  • CE

Loading...
In this segment, Caron A. Jacobson, MD, introduces the program and reviews current and emerging data surrounding CAR T-cell therapy.
person default
Caron A. Jacobson, MD
Program Director
Alix Beaupierre, BSN, RN, OCN
person default
Kathleen McDermott, RN, BSN, OCN, BMTCN
Registered Nurses: 2.0 Nursing contact hours
Released: July 8, 2020 Expiration: July 7, 2021
PreviousNext

Related Content

Expert slides on biologic principles, indications, and clinical biomarkers for immune checkpoint inhibitors, from Clinical Care Options (CCO)

Sandip P. Patel, MD Released: April 16, 2021

Expert slides on multidisciplinary management of immune-related adverse events associated with checkpoint inhibitors, from Clinical Care Options (CCO)

Marianne Davies, DNP, CNS, ACNP-BC, AOCNP Released: April 16, 2021

On-demand Clinical Care Options (CCO) webcast with experts’ review of data informing optimal management of relapsed/refractory myeloma

Shaji K. Kumar, MD
Program Director
Suzanne Lentzsch, MD, PhD Saad Z. Usmani, MD, MBA, FACP
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: March 31, 2021 Expired: March 30, 2022

From Clinical Care Options (CCO), read an expert commentary on how to safely provide CAR T-cell therapy during the COVID-19 pandemic

person default Caron A. Jacobson, MD Released: March 31, 2021

Video Chapters


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Celgene Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue